Effect of XXXX on @entity323 and improvement in the quality of sexual life in China: a multi-center study.

@entity1 @entity323 @entity7855
BACKGROUND: @entity323 ( @entity323 ) is a common medical condition in middle-aged and elderly @entity1 ; however, large-scale and multi-center epidemiologic studies about the treatment effects on @entity323 in China are lacking. OBJECTIVE: To elucidate the efficacy and safety of a phosphodiesterase type 5 inhibitor (PDE5-i) in the treatment of @entity1 with @entity323 in China. METHODS: @entity1 clinically diagnosed with @entity323 from 53 andrology centers in 15 metropolitan areas in China who were willing to undergo treatment for @entity323 were enrolled in the study. Each @entity1 received 4 weeks of unique PDE5-i treatment, and completed the following forms (International Index of Erectile Function score 5 [IIEF-5], the Erection Hardness Score [EHS], Self-Esteem and Relationship [SEAR], and SF-36 of Health Related Quality of Life). Pre-and post-treatment data were compared using descriptive analysis. RESULTS: A total of 1956 @entity323 @entity1 were included in this study; 1922 @entity1 provided valid questionnaires for analysis. Four weeks of @entity7855 treatment was considered effective and safe. Specifically, the IIEF-5 sores (11.30    3.7 vs. 20.02    5.1, P < 0.05), EHS levels (99.1% @entity1 increases to level 3 or 4), and the SEAR scores (32.5 vs. 55.1, P < 0.05) were significantly improved compared to baseline. @entity7855 therapy also significantly improved the satisfaction, enjoyment, and frequency of sexual attempts and sexual activity, as well as physical vigor and mental health scores. CONCLUSION: The present study provides direct evidence regarding the efficacy and safety of @entity7855 therapy in a large sample of Chinese @entity1 with @entity323 , thus verifying that @entity7855 improved the symptoms and quality of sexual life.
